Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto INSERISCI in fondo alla pagina
CINECA IRIS Institutional Research Information System
Infection of implantable cardiac devices is an emerging disease with significant morbidity, mortality, and health care costs.To describe the clinical characteristics and outcome of cardiac device infective endocarditis (CDIE) with attention to its health care association and to evaluate the association between device removal during index hospitalization and outcome.Prospective cohort study using data from the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS), conducted June 2000 through August 2006 in 61 centers in 28 countries. Patients were hospitalized adults with definite endocarditis as defined by modified Duke endocarditis criteria.In-hospital and 1-year mortality.CDIE was diagnosed in 177 (6.4\% [95\% CI, 5.5\%-7.4\%]) of a total cohort of 2760 patients with definite infective endocarditis. The clinical profile of CDIE included advanced patient age (median, 71.2 years [interquartile range, 59.8-77.6]); causation by staphylococci (62 [35.0\% {95\% CI, 28.0\%-42.5\%}] Staphylococcus aureus and 56 [31.6\% {95\% CI, 24.9\%-39.0\%}] coagulase-negative staphylococci); and a high prevalence of health care-associated infection (81 [45.8\% {95\% CI, 38.3\%-53.4\%}]). There was coexisting valve involvement in 66 (37.3\% [95\% CI, 30.2\%-44.9\%]) patients, predominantly tricuspid valve infection (43/177 [24.3\%]), with associated higher mortality. In-hospital and 1-year mortality rates were 14.7\% (26/177 [95\% CI, 9.8\%-20.8\%]) and 23.2\% (41/177 [95\% CI, 17.2\%-30.1\%]), respectively. Proportional hazards regression analysis showed a survival benefit at 1 year for device removal during the initial hospitalization (28/141 patients [19.9\%] who underwent device removal during the index hospitalization had died at 1 year, vs 13/34 [38.2\%] who did not undergo device removal; hazard ratio, 0.42 [95\% CI, 0.22-0.82]).Among patients with CDIE, the rate of concomitant valve infection is high, as is mortality, particularly if there is valve involvement. Early device removal is associated with improved survival at 1 year.
Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices.
Infection of implantable cardiac devices is an emerging disease with significant morbidity, mortality, and health care costs.To describe the clinical characteristics and outcome of cardiac device infective endocarditis (CDIE) with attention to its health care association and to evaluate the association between device removal during index hospitalization and outcome.Prospective cohort study using data from the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS), conducted June 2000 through August 2006 in 61 centers in 28 countries. Patients were hospitalized adults with definite endocarditis as defined by modified Duke endocarditis criteria.In-hospital and 1-year mortality.CDIE was diagnosed in 177 (6.4\% [95\% CI, 5.5\%-7.4\%]) of a total cohort of 2760 patients with definite infective endocarditis. The clinical profile of CDIE included advanced patient age (median, 71.2 years [interquartile range, 59.8-77.6]); causation by staphylococci (62 [35.0\% {95\% CI, 28.0\%-42.5\%}] Staphylococcus aureus and 56 [31.6\% {95\% CI, 24.9\%-39.0\%}] coagulase-negative staphylococci); and a high prevalence of health care-associated infection (81 [45.8\% {95\% CI, 38.3\%-53.4\%}]). There was coexisting valve involvement in 66 (37.3\% [95\% CI, 30.2\%-44.9\%]) patients, predominantly tricuspid valve infection (43/177 [24.3\%]), with associated higher mortality. In-hospital and 1-year mortality rates were 14.7\% (26/177 [95\% CI, 9.8\%-20.8\%]) and 23.2\% (41/177 [95\% CI, 17.2\%-30.1\%]), respectively. Proportional hazards regression analysis showed a survival benefit at 1 year for device removal during the initial hospitalization (28/141 patients [19.9\%] who underwent device removal during the index hospitalization had died at 1 year, vs 13/34 [38.2\%] who did not undergo device removal; hazard ratio, 0.42 [95\% CI, 0.22-0.82]).Among patients with CDIE, the rate of concomitant valve infection is high, as is mortality, particularly if there is valve involvement. Early device removal is associated with improved survival at 1 year.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/126088
Citazioni
ND
261
217
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione.
La simulazione si basa sui dati IRIS e presenta gli indicatori calcolati alla data indicata sul report. Si ricorda che in sede di domanda ASN presso il MIUR gli indicatori saranno invece calcolati a partire dal 1° gennaio rispettivamente del quinto/decimo/quindicesimo anno precedente la scadenza del quadrimestre di presentazione della domanda (art 2 del DM 598/2018).
In questa simulazione pertanto il valore degli indicatori potrà differire da quello conteggiato all’atto della domanda ASN effettuata presso il MIUR a seguito di:
Correzioni imputabili a eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori.
Presenza di eventuali errori di catalogazione e/o dati mancanti in IRIS
Variabilità nel tempo dei valori citazionali (per i settori bibliometrici)
Variabilità della finestra temporale considerata in funzione della sessione di domanda ASN a cui si partecipa.
La presente simulazione è stata realizzata sulla base delle regole riportate nel DM 598/2018 e dell'allegata Tabella A e delle specifiche definite all'interno del Focus Group Cineca relativo al modulo IRIS ER. Il Cineca non si assume alcuna responsabilità in merito all'uso che il diretto interessato o terzi faranno della simulazione.